Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lavior is an over-the-counter topical wound gel primarily intended for the treatment and management of diabetic wounds, including foot and leg ulcers. Its key active ingredient is allantoin (1% concentration), which acts as a skin protectant to promote wound healing and relieve dry, chafed, chapped, or cracked skin. The product is formulated with botanically derived and synthetic ingredients (including Inula viscosa extract, hyaluronate sodium, tocopheryl acetate/Vitamin E, etc.), designed to create and maintain a moist wound environment, facilitate autolytic debridement, and support the body’s natural repair processes. Lavior is hypoallergenic and specifically formulated for sensitive and diabetic skin. It is marketed by Lavior Pharma as a gentle and safe solution, endorsed by clinical trials and the American Diabetes Association for effective wound care[2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lavior.